Chinese Human Vaccine-Focused Biotech Firm Gets $36M In Series A Round

Chinese biotechnology firm Zhongyianke Biotech announced on Thursday that it has raised RMB250 million (US$36.35 million) in a series A round of financing from a group of investors including Chinese investment firm Shenzhen Qianhai Beizeng Asset Management.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets

LEAVE A REPLY